Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.04.17	Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda (RTTNews)
28.04.17	Sanofi: FDA Sets New Action Date For Kevzara BLA As May 22, 2017 - Quick Facts (RTTNews)
28.04.17	Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA (PR Newswire)
26.04.17	AKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE... (RTTNews)
25.04.17	Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection (PR Newswire)
24.04.17	Sanofi, Regeneron Say Kevzara Gets CHMP Positive Opinion For RA In Adults (RTTNews)
14.04.17	Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017 (PR Newswire)
05.04.17	Biotech Stocks on Investors' Radar -- Puma Biotechnology, Regeneron Pharma, Calithera, and Lexicon Pharma (PR Newswire)
29.03.17	First Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data (RTTNews)
29.03.17	Regeneron Says FDA Okays New Eczema Drug Dupixent (RTTNews)
28.03.17	Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval (PR Newswire)
28.03.17	Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
28.03.17	Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
23.03.17	U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis (PR Newswire)
15.03.17	Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017 (PR Newswire)
15.03.17	Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017 (PR Newswire)
07.03.17	Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions (PR Newswire)
05.03.17	Regeneron, Sanofi: DUPIXENT Study In Atopic Dermatitis Shows Positive Data (RTTNews)
27.02.17	Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Biotech Stocks Facing FDA Decision In March (RTTNews)
13.02.17	Regeneron Announces Upcoming 2017 Investor Conference Presentations (PR Newswire)
10.02.17	Regeneron Gets Subpoena On Patient Assistance Non-profit (RTTNews)
09.02.17	Regeneron Pharmaceuticals Reports 37% Rise In Q4 Profit (RTTNews)
09.02.17	Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results (PR Newswire)
09.02.17	AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban (RTTNews)
09.02.17	Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent (RTTNews)
08.02.17	Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process (PR Newswire)
01.02.17	Regeneron And Sanofi Say Canada Approves Kevzara (RTTNews)
01.02.17	Regeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada (PR Newswire)
24.01.17	Forty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists (PR Newswire)
23.01.17	Biotech Stocks Under Scanner -- Kite Pharma, BioPharmX, OvaScience, and Regeneron Pharma (PR Newswire)
10.01.17	Amgen Issues Statement On Court Decision On Patent Litigation (RTTNews)
06.01.17	MÄRKTE USA/Dow-Jones-Index scheitert hauchdünn an 20.000er Marke (Dow Jones)
06.01.17	Regeneron Remains Firmly Negative After Early Decline (RTTNews)
06.01.17	MÄRKTE USA/Arbeitsmarktdaten helfen Dollar mehr als Aktien (Dow Jones)
06.01.17	OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC (RTTNews)
06.01.17	Regeneron, Sanofi To Appeal U.S. Court Rulings In Patent Litigation On Praluent (RTTNews)
04.01.17	Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management (PR Newswire)
22.12.16	Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System (PR Newswire)
22.12.16	Science Publication Highlights the Precision Medicine Approach of Geisinger Health System and the Regeneron Genetics Center (PR Newswire)
08.12.16	Technical Reports on Biotech Equities -- Aurinia Pharma, Threshold Pharma, Regeneron Pharma, and INSYS Therapeutics (PR Newswire)
08.12.16	NWBO To Leave Nasdaq, Voyager Cruises Ahead, Watch Out For REGN (RTTNews)
08.12.16	Regeneron, Sanofi: EMA Accepts Dupixent Marketing Application For Review (RTTNews)
08.12.16	Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA (PR Newswire)
18.11.16	BSTC Finds New Use For Old Drug, FHCO Gets A Boost, SUPN Put On Notice (RTTNews)
04.11.16	Regeneron Pharmaceuticals Announces 32% Increase In Q3 Profit (RTTNews)
31.10.16	BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal (RTTNews)
17.10.16	Regeneron, Teva: FDA Places Phase 2b Fasinumab Back Pain Trial On Clinical Hold (RTTNews)
13.10.16	Ocular Therapeutix Signs Strategic Collaboration With Regeneron Pharma (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	203.30	0.35 %	K V
Givaudan	4’075.00	0.34 %	K V
Part Grp Hldg	1’269.00	0.16 %	K V
Alcon	76.40	0.10 %	K V
Lonza Grp	541.60	0.04 %	K V
Swisscom	505.00	-0.39 %	K V
Swiss Re	131.05	-0.68 %	K V
Logitech Intl	74.30	-0.75 %	K V
UBS Group	27.90	-0.96 %	K V
Nestle	74.46	-1.01 %	K V

mehr

17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone
05.12.24		Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer
19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone